Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 7/20 | 0.64 |
| ▸ | GRIN2A known ✓ | Q12879 | 7/20 | 0.64 |
| ▸ | GRIN2D known ✓ | O15399 | 6/20 | 0.60 |
| ▸ | GRIN3B known ✓ | O60391 | 6/20 | 0.60 |
| ▸ | GRIN2B known ✓ | Q13224 | 6/20 | 0.60 |
| ▸ | GRIN2C known ✓ | Q14957 | 6/20 | 0.60 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 6/20 | 0.60 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.60 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.60 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.60 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.60 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.64 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.60 |
| ▸ | MTOR | P42345 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1764807 | 0.98 | GRIN1 (0.62) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| SCHEMBL25552171 | 0.98 | GRIN1 (0.62) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| Hydrochloric Acid SCHEMBL866896 | 0.82 | LMNA (0.67) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| Hydrochloric Acid SCHEMBL28669825 | 0.82 | GRIN1 (0.50) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| Hydrochloric Acid SCHEMBL1880961 | 0.82 | LMNA (0.67) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| SCHEMBL1938959 | 0.80 | GRIN1 (0.47) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| Memantine SCHEMBL249401 | 0.79 | GRIN1 (0.86) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| Memantine SCHEMBL1374768 | 0.79 | GRIN1 (0.86) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| SCHEMBL12132159 | 0.79 | GRIN1 (0.65) | GRIN1GRIN2ALMNAPMP22NPSR1 | |
| SCHEMBL733849 | 0.79 | GRIN1 (0.48) | GRIN1GRIN2ALMNAPMP22NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119936252-A | Memantine hydrochloride and detection method of related substances thereof | 宁夏医科大学 | 2025-05-06 | — | — | CN | claimed |
| EP-2555616-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | Hetero Research Foundation (IN) | 2013-02-13 | — | — | EP | claimed |
| WO-2011125062-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2011-10-13 | — | — | WO | claimed |
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV BARCELONA (ES) | 2026-04-02 | — | — | US | disclosed |
| EP-4676916-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Universitat De Barcelona (ES) | 2026-01-14 | — | — | EP | disclosed |
| CN-119936252-A | Memantine hydrochloride and detection method of related substances thereof | 宁夏医科大学 | 2025-05-06 | — | — | CN | disclosed |
| CN-119936252-A | Memantine hydrochloride and detection method of related substances thereof | 宁夏医科大学 | 2025-05-06 | — | — | CN | disclosed |
| WO-2024184305-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITAT DE BARCELONA (ES) | 2024-09-12 | — | — | WO | disclosed |
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-07 | — | — | US | disclosed |
| CN-107334744-B | Memantine hydrochloride medicine composition and preparation method thereof | 湖南洞庭药业股份有限公司 | 2020-09-04 | — | — | CN | disclosed |
| EP-2555616-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | Hetero Research Foundation (IN) | 2013-02-13 | — | — | EP | disclosed |
| EP-2555616-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | Hetero Research Foundation (IN) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011125062-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011125062-A1 | PROCESS FOR THE PREPARATION OF MEMANTINE HYDROCHLORIDE | HETERO RESEARCH FOUNDATION (IN) | 2011-10-13 | — | — | WO | disclosed |
| EP-1999100-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2008-12-10 | — | — | EP | disclosed |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007126886-A1 | PROCESS FOR PREPARING MEMANTINE HYDROCHLORIDE SUBSTANTIALLY FREE OF IMPURITIES | TEVA PHARMACEUTICALS USA, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597727-B2 | Inhibitors of integrin alpha 2 beta 1 and methods of use | ITGB1, ITGB2, ITGA2 | GRIN1 933/4885GRIN2A 918/4885GRIN2D 830/4885 |
| US-20080033054-A1 | Process for preparing memantine hydrochloride substantially free of impurities | PNMT, PSEN2, CHRNA5 | GRIN1 83/4885GRIN2A 16/4885GRIN2D 68/4885 |
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE2, BACE1, GLS2 | GRIN1 31/4885GRIN2A 41/4885GRIN2D 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.